Table 3.
Univariate outcomes of patients who underwent allogeneic bone marrow or peripheral blood transplantation for mycosis fungoides and Sezary syndrome, registered with the CIBMTR, between 2000 – 2009a.
| Outcome of interest | N(eval) | Probability (95 % CI) |
|---|---|---|
| Total number of patients | 129 | |
| Mortality | ||
| @ 30 days | 129 | 6 (3–11) |
| @ 100 days | 16 (10–23) | |
| Neutrophil engraftment | 110 | |
| @ 28 days | 95 (88–98) | |
| @ 100 days | 95 (89–98) | |
| Platelet engraftment (20,000 × 109/L) | 53 | |
| @ 28 days | 70 (55–81) | |
| @ 100 days | 89 (76–95) | |
| Acute GVHD | 95 | |
| Grade II–IV @ 100 days | 41 (32–51) | |
| Chronic GVHD | 87 | |
| @ 180 days | 33 (23–43) | |
| @ 1 year | 42 (31–52) | |
| @ 2 years | 43 (33–54) | |
| Non relapsed mortality | 119 | |
| @ 1 year | 19 (12–27) | |
| @ 3 year | 22 (15–31) | |
| @ 5 year | 22 (15–31) | |
| Progression relapse | 119 | |
| @ 1 year | 50 (41–60) | |
| @ 3 year | 58 (48–68) | |
| @ 5 year | 61 (50–71) | |
| Progression free survival | 119 | |
| @ 1 year | 31 (22–40) | |
| @ 3 year | 19 (12–28) | |
| @ 5 year | 17 (9–26) | |
| Overall survival | 129 | |
| @ 1 year | 54 (45–63) | |
| @ 3 year | 38 (28–48) | |
| @ 5 year | 32 (22–44) | |
Abbreviations: GVHD= graft vs. host disease
Probabilities of overall survival, mortality and progression free survival were calculated using the Kaplan-Meier product limit estimate.
Probability of neutrophil & platelet engraftment, treatment related mortality, progression relapse, AGVHD and CGVHD were calculated using the cumulative incidence function.